title: [Chemotherapy of a 2-week S-1 administration followed by 1-week rest for advanced and metastatic breast cancer].
abstract: When treating advanced and metastatic breast cancer patients with chemotherapy, it is mandatory to maintain the patients quality of life while keeping an acceptable level of antitumor activity. For these purposes, oral administration of S-1, fluorinated pyrimidine, is a good choice of treatment. Conventionally, a 4-week administration followed by a 2-week rest has been the treatment of choice with S-1. However, we applied a new regimen for 16 patients with advanced and metastatic breast cancer, in which one course consisted of a 2 week-administration followed by a week of rest, repeated twice. The median age of the patients who received this treatment was 59 years old(range 46. 8-80. 6). The response rate was 31. 2%, and the median values of time to progression and overall survival were 5. 1 and 17. 9 months, respectively. One case of thrombocytopenia as an adverse event was recognized. Our new S-1 regimen is likely to show an acceptable anti-tumor effect with minimal adverse events. The fidings suggest that this new regimen is clinically applicable for advanced and metastatic breast cancer patients.
authors.affiliation: Dept. of Surgery, Division of Breast and Endocrine Surgery, Aichi Medical University.
authors.forename: Kimihito
authors.initials: K
authors.lastname: Fujii
authors.forename: Junko
authors.initials: J
authors.lastname: Kosaka
authors.forename: Yukako
authors.initials: Y
authors.lastname: Mouri
authors.forename: Miwa
authors.initials: M
authors.lastname: Yoshida
authors.forename: Kyoko
authors.initials: K
authors.lastname: Yorozuya
authors.forename: Shogo
authors.initials: S
authors.lastname: Nakano
authors.forename: Miwa
authors.initials: M
authors.lastname: Akizuki
authors.forename: Takashi
authors.initials: T
authors.lastname: Fukutomi
authors.forename: Katsumasa
authors.initials: K
authors.lastname: Kobayashi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D004338:Drug Combinations; D005260:Female; D006801:Humans; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use; D005641:Tegafur / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid